Closed Loop Medicine grows US patent portfolio
Founded at the Babraham Institute in Cambridge, the company says that strengthening its cardiometabolic treatment portfolio, means it now has patents covering advancements in GLP-1 therapies for obesity and diabetes plus direct oral anticoagulants for cardiovascular health.
Closed Loop Medicine holds over 65 filings across 16 patent families, marking a significant milestone in its mission to deliver precision medicine at scale.
The company continues to expand its strong IP foundation to safeguard the scalability of its innovations in personalised dosing, novel drug forms and drug-digital combination therapies.
In the rapidly-established GLP-1 market, Closed Loop Medicine has recognised the potential in delivering personalised solutions that address both the unpredictability of weight loss and the adverse effects that may otherwise limit patient adherence to weight management programs.
The company’s IP covers dose optimisation according to patient-specific factors such as degree of calorie restriction or exercise, providing an opportunity for the development of personalised co-therapies enhancing existing GLP-1 medicines.
The latest patent granted by the US Patent Office extends Closed Loop Medicine’s cardiometabolic capabilities into DOAC therapy, enabling more personalised and effective anticoagulation treatment.
This patent supports AI-powered precision dosing for patients requiring DOACs, improving safety and efficacy in stroke prevention and other cardiovascular conditions.
Dr. Hakim Yadi, CEO and co-Founder of Closed Loop Medicine, says: “Establishing a strong and differentiated patent portfolio is central to our leadership in AI-enabled personalised medicine.
“These patents reinforce our ability to deliver smarter, AI-enabled pharmacometric dosing solutions – not only to improve clinical outcomes and optimise treatment for cardiometabolic diseases with novel drug forms, but also software enhancements of existing drugs, the latter receiving timely support with the FDA’s recent Prescription Drug Use-Related Software PDURS guidance.”